Xanax XR Lot #8177156: Anxiety Medication Recalled by Viatris, What's the Cause?

Liputan6.com, Jakarta - Viatris Specialty, LLC, a pharmaceutical company based in West Virginia, announced a voluntary recall of one lot of Xanax XR, specifically targets 3 mg extended-release alprazolam tablets in bottles containing 60 tablets.

The recalled product was distributed in the United States between August 27, 2024, and May 29, 2025.

The primary reason behind this recall is that the product "failed to meet dissolution specifications," that may not dissolve at a standard rate or may not release the correct dose into the body.

This condition could potentially result in a less effective medication or an incorrect dose for the patient.

The Food and Drug Administration (FDA) classified this recall as Class II on April 8, 2026, indicating the possibility of temporary or reversible adverse health consequences.

Anxiety drug Xanax recalled nationwide: How to check if your prescription is included https://t.co/mVVZ6fPXuC pic.twitter.com/mAFK7kFv1K

— New York Post (@nypost) April 15, 2026

This recall exclusively affects Xanax XR lot number #8177156 with an expiration date of February 28, 2027.

This medication is a 3 mg tablet packaged in bottles of 60 tablets and the lot number and expiration date can be found on the bottle label.

Viatris Inc. first initiated this recall process on March 17, 2026, before the FDA officially classified it.

The recalled Xanax XR products were manufactured in Ireland and distributed in the United States lasted from late August 2024 to late May 2025.

Xanax, generically named alprazolam, is a benzodiazepine commonly prescribed to treat panic disorder and generalized anxiety disorder in adults.

Alprazolam is known to be one of the most commonly prescribed benzodiazepines in the United States.

Failure to dissolution specification means that a medication does not dissolve its active ingredient properly or at the expected rate.

In the context of extended-release medications like Xanax XR, this can mean the drug is released too quickly or too slowly.

This inconsistent release can prevent patients from getting the full therapeutic effect of their prescription.

For individuals who rely on a stable daily dose to manage conditions such as anxiety or panic disorders, inconsistent absorption can pose a serious clinical problem.

Incorrect dosing can disrupt the patient's stability, potentially worsening symptoms or causing unwanted side effects.

As of the time of this publication, there have been no reports of illness or death directly related to this Xanax recall.

However, the risk of potential health effects remains a major concern.

The FDA classifies this recall as Class II, indicating that use or exposure to the affected product may cause temporary or medically reversible adverse health consequences.

This classification provides an overview of the risk level assessed by health authorities.

Patients who encounter Xanax XR with lot number #8177156 are advised to immediately contact their healthcare professional.

This includes the pharmacist or the prescribing physician.

It is crucial not to abruptly stop taking Xanax without consulting a doctor.

Abruptly stopping medications for mood disorders like alprazolam can trigger more severe withdrawal symptoms or more serious consequences.

A healthcare professional will assist with any necessary medication transitions or adjustments.

Sources:

https://www.fox13news.com/news/xanax-popular-anxiety-medication-recalled-what-know

https://nypost.com/2026/04/15/business/xanax-recalled-nationwide-how-to-check-if-your-anxiety-medication-is-included/

https://people.com/xanax-anxiety-drug-has-been-recalled-nationwide-11951111